fsoalex, There are not, to my knowledge, any ap

fsoalex,

There are not, to my knowledge, any approved therapies for NASH or NAFLD. The only recommendation I find it weight loss, as excess adipose tissue drives inflammation. The leronlimab results, though open label from a handful of patients, may be clinically significant, especially over the short 13-week treatment period. The placebo controlled trial will be more indicative. The degree of improvement counts, but also the incidence of improvement versus placebo.

There are quite a number of evaluation metrics with which I am not familiar, so while the reduction in fat fraction and fibrosis appears significant to me, it may not be. Lanfibranor, recently showed improvement recently using the SAF-A score, but I don't know how that is measured and how it compares to the imaging results Cytodyn used.

The two mostly widely accepted metrics I believe are liver biopsy and MRI-PDFF which are less subjective than the ultrasound results reported in this handful of patients.

As multiple others have posted today, the results are intriguing but truly we need results from the double blinded, placebo controlled P2 study to draw any conclusions.